Speaking to Yahoo Finance on Thursday, Jefferies analyst Michael Yee said the “overly high expectations” set last year, as Moderna’s Covid-19 vaccine became widely available to the public, will “lead to challenges . as people digest” what’s next for the firm beyond Covid vaccines. Once the pandemic hit, the company doubled down on the efforts and filed for an emergency use authorization for its Covid-19 vaccine in November 2020. In addition to lower sales projections, supply chain constraints and the development of antiviral Covid-19 treatments have also dented investor sentiment—and triggered Moderna stock selloffs. Further ReadingModerna Crash Wipes Out Another $24 Billion After Supply-Chain Issues Dent Covid Vaccine Sales (Forbes)Full coverage and live updates on the Coronavirus

Source: Forbes January 22, 2022 19:39 UTC